XML 28 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Customer and Supplier Concentration
9 Months Ended
Sep. 30, 2021
Customer and Supplier Concentration  
Customer and Supplier Concentration

Note 7. Customer and Supplier Concentration

Customer Concentrations

Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc., or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. The Company considers these three customers to be its major customers, as each individually, and these customers collectively, represented a significant percentage of the Company’s net revenue for the three and nine months ended September 30, 2021 and 2020, and accounts receivable as of September

30, 2021 and December 31, 2020, respectively. The following table provides accounts receivable and net revenue information for these major customers:

% of Total Accounts

% of Net

Receivable

Revenue

Three Months Ended

Nine Months Ended

 

September 30, 

December 31, 

September 30, 

September 30, 

    

2021

    

2020

    

2021

    

2020

    

2021

 

2020

 

AmerisourceBergen

 

15

%

9

%

25

%

23

%

24

%

23

%

McKesson

 

23

%

24

%

21

%

21

%

20

%

22

%

Cardinal Health

 

20

%

17

%

18

%

17

%

16

%

18

%

Supplier Concentrations

The Company depends on suppliers for raw materials, APIs, and other components that are subject to stringent FDA requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.